At a Glance
- Company: Samsung Biologics
- Location: Incheon, South Korea; Rockville, Maryland, USA
- Deal value: Plant 6 construction trigger; 7tn won Bio Campus 3 investment to 2034
- Focus area: Large‑scale biologics, ADCs, vaccines, cell/gene therapies; US onshoring
- Next steps: Ramp Plant 5; integrate Rockville; build multimodality campus
What happened?
Samsung Biologics presented a three‑pillar CDMO expansion strategy at JPM26: boosting large‑scale biologics capacity, developing multimodality capabilities and diversifying geographically to meet outsourcing demand. CEO John Rim highlighted Plant 6 construction on Bio Campus 2, Rockville integration and a new multimodality Bio Campus 3 with 7 trillion won investment through 2034.
Why does it matter?
Biologics CDMO market growth (8–10% CAGR) is driven by complex modalities like ADCs and CGT, where scale, flexibility and regional proximity are critical. Samsung’s plan—adding 845,000L capacity, ADC/CGT suites and US hubs—positions it to win mandates from global pharmas facing supply risks and regulatory pressures.
Who’s behind it?
Samsung Biologics is a top‑five global CDMO with 640,000L capacity (Plants 1–5), 62+ approvals and ExellenS digital manufacturing. The Rockville GSK acquisition adds US biologics/ADC scale.
How was it achieved?
Pillar 1 scales antibody production (Plant 6); Pillar 2 builds Bio Campus 3 for ADCs/vaccines/CGT; Pillar 3 embeds Rockville and explores further US/EU sites under digital twin/AI frameworks.
What’s next?
Trigger Plant 6 construction, ramp Plant 5/Rockville and advance Bio Campus 3, targeting end‑to‑end CRDMO leadership.
What are people saying?
CEO John Rim said the pillars “maximise productivity” for a sustainable future. Analysts see it solidifying Samsung as a “super CDMO” amid outsourcing boom.